Influx Flow Cytometer

流入流式细胞仪

• 批准号: 8447644
• 负责人: FREDERIC Ira PREFFER
• 金额: $ 60万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-06-20 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8447644
• 关键词: Age; Boston; Budgets; Cells; Cellular biology; Clinical; Communicable Diseases; Communities; Cytometry; Engineering; Environment; Financial Support; Flow Cytometry; Fluorescence; Funding; Gases; General Hospitals; Genetic; Grant; Hospital Administration; Hospital Units; Hospitals; Human; Immunology; Ions; Laboratories; Laboratory Research; Lasers; Massachusetts; Molecular Biology; National Center for Research Resources; Optical Instrument; Pathology; Research; Research Personnel; Resources; Sorting - Cell Movement; Stem Cell Research; Translational Research; United States National Institutes of Health; Universities; Work; base; design; experience; improved; instrument; instrumentation; multidisciplinary; oncology; operation

DESCRIPTION (provided by applicant): NIH funds are requested to purchase a BD Influx cell sorter that will be placed in the PI's 870 ft2 research laboratory at Massachusetts General Hospital (MGH) in Boston. The Influx is a 6- laser instrument that is a vastly improved, refined and a far more powerful cell sorter than that it will replace, the FACS Vantage. The Vantage was initially designed in the 1990s and purchased by the PI with NCRR funds in 2000; two of the four ion-gas lasers on this instrument's optical bench are over 25 years old. Due to its chronologic age, the Vantage is increasingly difficult to maintain. Far more critically, from an engineering and technological perspective it no longer offers the necessary fluorescence sensitivity, cellular throughput and high capacity 6-way sorting ability that our user base requires. Also, a rapidly increasing translational research emphasis has accentuated the need for safe, bio-contained sorting capabilities of human cells beyond the capacity of our current sorting platform. Thus, the requested Influx will be configured additionally with a Baker class II Type A2 certified HEPA filtered biosafety hood that will provide far greater protection to the operator and local environment. The requested Influx will be placed in the PI's well established Flow Cytometry Core which has been in successful operation for almost 30 years. A wide variety of studies related to cell biology, immunology, genetics, molecular biology, infectious disease, oncology and stem cell research will all benefit from the placement of this instrumentation in the PI's facility. The PI has an established track record in utilizing polychromatic cytometry for both research and clinical work and documents that the requested instrument will provide an essential resource to the needs of the research user base at MGH. This instrument will initially serve a multidisciplinary group of 28 primary investigators from 9 departments and numerous MGH Units, representing 78 NIH funded grants totaling over 44.8 million dollars. The Influx will further benefit the entire research community at MGH, who presently lack a modern cell-sorter for their NIH funded work. The entire hospital of approximately 1000 PI's has a NIH budget of about $325 million dollars. The PI has been part of the MGH research community since 1982, and his laboratory has been the only one easily available to all investigators at MGH. The laboratory has a highly skilled operator, who along with the PI collectively represents almost 60 years of well-documented experience in flow cytometry. The laboratory has the financial support of both the Department of Pathology and MGH administration and approval of the University Biosafety office for the projects outlined in this submission.

描述（由申请人提供）：要求购买NIH资金购买BD涌入细胞分系程序，该分隔器将放置在波士顿马萨诸塞州综合医院（MGH）的PI 870 FT2研究实验室中。涌入是一种6个激光器仪器，它是一种大大改进，精制和强大的细胞分落器，而不是它会取代FACS Vantage。 Vantage最初是在1990年代设计的，并于2000年由NCRR基金购买；该乐器光学台上的四个离子气体激光器中有两个超过25年。由于其年代年龄，因此有利的维护越来越难以维持。更重要的是，从工程和技术角度来看，它不再提供我们用户基础所需的必要的荧光灵敏度，细胞吞吐量和高容量的6向分类能力。此外，迅速增加的转化研究重点增强了人们对当前分类平台的能力之外人类细胞安全，具有生物含量的分类能力的需求。因此，将使用Baker II类A2认证的HEPA过滤的生物安全罩以及将为操作员和当地环境提供更大保护的Baker II类A2类型式II类式涌入。所请求的涌入将放置在PI已建立的流式细胞仪核心中，该流式细胞仪核心已成功运营已有近30年的历史。与细胞生物学，免疫学，遗传学，分子生物学，传染病，肿瘤学和干细胞研究有关的各种研究都将受益于该仪器在PI的设施中的放置。 PI在利用多色细胞仪进行研究和临床工作和文档中具有既定的往绩，该仪器将为MGH的研究用户群提供必需的资源。该工具最初将为来自9个部门和许多MGH单位的28个主要调查人员组成的多学科小组，代表78个NIH资助的赠款，总计超过4480万美元。涌入将进一步使MGH的整个研究界受益，他们目前缺乏现代的NIH资助工作。大约1000 PI的整个医院的NIH预算约为3.25亿美元。自1982年以来，PI一直是MGH研究社区的一部分，他的实验室是MGH所有研究人员唯一可用的实验室。该实验室有一个高技能的操作员，他与PI共同代表了将近60年的流式细胞仪经验。该实验室得到了病理学系和MGH行政部的财政支持，并获得了本提交中概述的项目生物安全办公室的批准。